Patients with chronic rhinosinusitis with nasal polyps were found to benefit more from the combination of endoscopic sinus surgery plus medical therapy vs medical therapy alone, although the minimal clinically important difference was not met.
Endoscopic sinus surgery (ESS) plus medical therapy may be more effective vs medical therapy alone in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), according to study findings published in The Lancet Respiratory Medicine.
Typically performed when patients with CRSwNP are unresponsive to medical therapy alone, ESS has been shown in prior research to significantly improve symptoms and health-related quality of life (HRQOL). However, more than 1 in 5 patients (20%–30%) have been indicated to require revision ESS after 5 to 10 years.
“Large variations in the management of CRSwNP exist both between and within countries and among individual specialists, which can lead to inefficient and inappropriate care,” said the study authors. “The positioning of ESS plus medical therapy in patients with CRSwNP has been identified by the UK National Institute of Health and Care Excellence, the European Rhinologic Society, and the Dutch Society of Otorhinolaryngology and Head and Neck Surgery as one of the most important knowledge gaps in otorhinolaryngology.”
With no randomized controlled trials having explored the efficacy of ESS, they conducted an open-label, multi-center, pragmatic, randomized, controlled trial to compare treatment outcomes of ESS plus medical therapy vs medical therapy alone in patients with CRSwNP.
In the study, adults aged 18 years and older with CRSwNP and an indication for ESS were recruited from 3 tertiary care centers and 12 secondary care centers in 11 cities in the Netherlands between February 15, 2015 and August 27, 2019. Participants were randomly assigned at a 1:1 ratio to receive either ESS plus medical therapy or medical therapy alone, such as nasal corticosteroids, nasal rinsing, systemic corticosteroids, or systemic antibiotics.
“ESS was performed according to local practice, although anterior ethmoidectomy was mandatory,” they noted. “Primary and safety analyses were performed on an intention-to-treat (ITT) basis.”
The primary outcome assessed was disease-specific HRQOL at 12 months of follow up, measured with the validated Sinonasal Outcome Test 22 (SNOT-22), in which each item is scored from 0 to 5 based on severity with a total score of 0 to 110 points. The minimal clinically important difference of the SNOT-22 was identified at 9.0 points.
Of the 238 patients eligible for analysis, 121 were randomly assigned to ESS plus medical therapy and 117 were given medical therapy alone, with 234 included in the baseline ITT population (ESS plus medical therapy, n = 118; medical therapy, n = 116).
After 12 months, 103 patients given ESS plus medical therapy and 103 treated with medical therapy alone were analyzed for the primary outcome. Findings of the 12-month follow-up showed that the mean (SD) SNOT-22 score was 27.9 (20.2) in the ESS plus medical therapy group and 31.1 (20.4) in the medical therapy group, with an adjusted mean difference of –4.9 (95% CI, –9.4 to –0.4) favoring ESS plus medical therapy.
“ESS plus medical therapy is more efficacious than medical therapy alone in patients with CRSwNP, although the minimal clinically important difference was not met.”
Regarding safety, adverse events were similar between the groups, with the most common adverse events cited as minor epistaxis or gastrointestinal problems.
“Long-term follow-up data are needed to determine whether the effect persists. The current results are a basis for further development of evidence-based guidelines.”
Reference
Lourijsen ES, Reitsma S, Vleming M, et al. Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial. Lancet Respir Med. Published online January 7, 2022. doi:10.1016/S2213-2600(21)00457-4
AA Unlikely to Cause Anxiety, Depression but May Be Affected by Mental Illness
May 7th 2024A Mendelian randomization study using genetic analysis found that alopecia areata (AA) increases the risk of anxiety and depression, but not the other way around, providing unique evidence for a causal link while adding to existing evidence.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Following Roe v Wade Overturn, Research Focuses on Male Contraceptives
May 6th 2024Stephanie T. Page, MD, PhD, UW Medicine Diabetes Institute, presented on ongoing research and growing interest in new male contraceptive options, such as an oral pill and a hormonal transdermal gel, at the American Urological Association 2024 Annual Meeting.
Read More